Sentinel node status predicts survival in thick melanomas: the Oxford perspective.
AIMS: To determine the prognostic value of SLNB in patients with thick melanoma in terms of overall survival (OS) and recurrence-free survival (RFS). METHODS: 136 patients with primary tumours (Breslow thickness ≥ 4.0 mm) underwent SLNB. OS and RFS were calculated and a multivariate Cox regression...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797092385183760384 |
|---|---|
| author | Rughani, MG Swan, M Adams, T Marshall, A Asher, R Cassell, O Middleton, MR |
| author_facet | Rughani, MG Swan, M Adams, T Marshall, A Asher, R Cassell, O Middleton, MR |
| author_sort | Rughani, MG |
| collection | OXFORD |
| description | AIMS: To determine the prognostic value of SLNB in patients with thick melanoma in terms of overall survival (OS) and recurrence-free survival (RFS). METHODS: 136 patients with primary tumours (Breslow thickness ≥ 4.0 mm) underwent SLNB. OS and RFS were calculated and a multivariate Cox regression model used to determine the important prognostic factors for predicting OS and RFS. RESULTS: Median Breslow thickness was 5.5 mm and 60% were ulcerated. Median follow up was 4 years (95% CI = 4-5) with 54 patients having died at the time of analysis. 5-year OS for SLNB positive patients was 32%, compared to 78% for negative patients. The significant predictors of poorer OS were increasing age (p = 0.03), increasing Breslow thickness (p = 0.03) and SLNB positivity (p < 0.0001). 5 year RFS was significantly worse in the SLNB positive population compared to the negative patients (p < 0.0001); 27% versus 66% respectively. CONCLUSIONS: Patients with a thick melanoma and a positive SLNB have a significantly worse RFS and OS compared to those with a negative SLNB. Over three-quarters of patients with a negative SLNB survived five years. These findings have implications for the subpopulations included in adjuvant therapy trials and we advocate SLNB be recommended in patients with thick melanomas. |
| first_indexed | 2024-03-07T03:45:14Z |
| format | Journal article |
| id | oxford-uuid:bf3f12da-4abc-4a84-a652-1505a7cdaa06 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:45:14Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:bf3f12da-4abc-4a84-a652-1505a7cdaa062022-03-27T05:46:01ZSentinel node status predicts survival in thick melanomas: the Oxford perspective.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bf3f12da-4abc-4a84-a652-1505a7cdaa06EnglishSymplectic Elements at Oxford2012Rughani, MGSwan, MAdams, TMarshall, AAsher, RCassell, OMiddleton, MR AIMS: To determine the prognostic value of SLNB in patients with thick melanoma in terms of overall survival (OS) and recurrence-free survival (RFS). METHODS: 136 patients with primary tumours (Breslow thickness ≥ 4.0 mm) underwent SLNB. OS and RFS were calculated and a multivariate Cox regression model used to determine the important prognostic factors for predicting OS and RFS. RESULTS: Median Breslow thickness was 5.5 mm and 60% were ulcerated. Median follow up was 4 years (95% CI = 4-5) with 54 patients having died at the time of analysis. 5-year OS for SLNB positive patients was 32%, compared to 78% for negative patients. The significant predictors of poorer OS were increasing age (p = 0.03), increasing Breslow thickness (p = 0.03) and SLNB positivity (p < 0.0001). 5 year RFS was significantly worse in the SLNB positive population compared to the negative patients (p < 0.0001); 27% versus 66% respectively. CONCLUSIONS: Patients with a thick melanoma and a positive SLNB have a significantly worse RFS and OS compared to those with a negative SLNB. Over three-quarters of patients with a negative SLNB survived five years. These findings have implications for the subpopulations included in adjuvant therapy trials and we advocate SLNB be recommended in patients with thick melanomas. |
| spellingShingle | Rughani, MG Swan, M Adams, T Marshall, A Asher, R Cassell, O Middleton, MR Sentinel node status predicts survival in thick melanomas: the Oxford perspective. |
| title | Sentinel node status predicts survival in thick melanomas: the Oxford perspective. |
| title_full | Sentinel node status predicts survival in thick melanomas: the Oxford perspective. |
| title_fullStr | Sentinel node status predicts survival in thick melanomas: the Oxford perspective. |
| title_full_unstemmed | Sentinel node status predicts survival in thick melanomas: the Oxford perspective. |
| title_short | Sentinel node status predicts survival in thick melanomas: the Oxford perspective. |
| title_sort | sentinel node status predicts survival in thick melanomas the oxford perspective |
| work_keys_str_mv | AT rughanimg sentinelnodestatuspredictssurvivalinthickmelanomastheoxfordperspective AT swanm sentinelnodestatuspredictssurvivalinthickmelanomastheoxfordperspective AT adamst sentinelnodestatuspredictssurvivalinthickmelanomastheoxfordperspective AT marshalla sentinelnodestatuspredictssurvivalinthickmelanomastheoxfordperspective AT asherr sentinelnodestatuspredictssurvivalinthickmelanomastheoxfordperspective AT cassello sentinelnodestatuspredictssurvivalinthickmelanomastheoxfordperspective AT middletonmr sentinelnodestatuspredictssurvivalinthickmelanomastheoxfordperspective |